PPARalpha ligands and clinical trials: cardiovascular risk reduction with fibrates.
Robins
S J
SJ
Department of Medicine, Boston University School of Medicine, Massachusetts 02118, USA. sjrobins@bu.edu
D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear / Q000627:therapeutic use*; D012307:Risk Factors; D014157:Transcription Factors / Q000627:therapeutic use*
D000960:Hypolipidemic Agents; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D002784:Cholesterol